Ibrutinib and novel BTK inhibitors in clinical development

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Akinleye, Akintunde, Chen, Yamei, Mukhi, Nikhil, Song, Yongping, Liu, Delong
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751776/
https://ncbi.nlm.nih.gov/pubmed/23958373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-59
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi